



- (51) **International Patent Classification:**
C07K 7/54 (2006.01) *A61P 35/00* (2006.01)
A61K 38/12 (2006.01)
- (21) **International Application Number:**
PCT/US2015/065723
- (22) **International Filing Date:**
15 December 2015 (15.12.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/094,008 18 December 2014 (18.12.2014) US
- (71) **Applicant:** BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).
- (72) **Inventors:** MAPELLI, Claudio; c/o Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US). GILLIS, Eric P.; c/o Bristol-My-
ers Squibb Company, 5 Research Parkway, Wallingford,
Connecticut 06492 (US). SUN, Li-Qiang; c/o Bristol-My-
ers Squibb Company, 5 Research Parkway, Wallingford,
Connecticut 06492 (US). ZHAO, Qian; 93 Hintz Drive,
Wallingford, CT 06492 (US). ALLEN, Martin Patrick;
c/o Bristol-Myers Squibb Company, Route 206 and
Province Line Road, Princeton, New Jersey 08543 (US).
MULL, Eric; c/o Bristol-Myers Squibb Company, 5 Re-
search Parkway, Wallingford, Connecticut 06492 (US).
SCOLA, Paul Michael; c/o Bristol-Myers Squibb Com-
pany, 5 Research Parkway, Wallingford, Connecticut
06492 (US).
- (74) **Agents:** MINGO, Pamela A. et al.; Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** IMMUNOMODULATORS

(57) **Abstract:** The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

